Cargando…

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes

BACKGROUND: Immunotherapy targeting the programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint has shown the good outcomes in non-small cell lung cancer (NSCLC). We investigated PD-1 and PD-L1 protein expression and their correlation with tumor-infiltrating lymphocytes (TILs), and as...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Yayi, Rozeboom, Leslie, Rivard, Christopher J., Ellison, Kim, Dziadziuszko, Rafał, Yu, Hui, Zhou, Caicun, Hirsch, Fred R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2017
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356616/ https://www.ncbi.nlm.nih.gov/pubmed/28275222 http://dx.doi.org/10.12659/MSM.899909

Ejemplares similares

Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer
por: He, Yayi, et al.
Publicado: (2016)

Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer
por: Sun, Chenglong, et al.
Publicado: (2020)

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma
por: Cao, Jinfeng, et al.
Publicado: (2017)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules
por: He, Yayi, et al.
Publicado: (2017)

Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer
por: Buisseret, Laurence, et al.
Publicado: (2016)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
por: He, Yayi, et al.
Publicado: (2018)

Loss of STING expression is prognostic in non–small cell lung cancer
por: Lohinai, Zoltan, et al.
Publicado: (2022)

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
por: Kitano, Atsuko, et al.
Publicado: (2017)

Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8(+) Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer
por: Munari, Enrico, et al.
Publicado: (2021)

Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status
por: Suda, Kenichi, et al.
Publicado: (2017)

PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC
por: Ameratunga, Malaka, et al.
Publicado: (2016)

PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms
por: Higuchi, Rumi, et al.
Publicado: (2019)

Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas
por: Kim, Jung Ryul, et al.
Publicado: (2013)

PD-L1(+) tumor-associated macrophages and PD-1(+) tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma
por: Pollari, Marjukka, et al.
Publicado: (2018)

Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer
por: Li, Yaqi, et al.
Publicado: (2016)

Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies
por: Larroquette, Mathieu, et al.
Publicado: (2022)

Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups
por: Tomassen, T., et al.
Publicado: (2022)

Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival
por: Liu, Jingwei, et al.
Publicado: (2020)

Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
por: Harter, Patrick N., et al.
Publicado: (2015)

Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 Efficacy
por: Ballot, Elise, et al.
Publicado: (2020)

PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
por: Martin de la Fuente, Laura, et al.
Publicado: (2020)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

PD-L1 is increased in the spinal cord and infiltrating lymphocytes in experimental allergic encephalomyelitis
por: Li, Min, et al.
Publicado: (2013)

Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma
por: Noh, Byeong-Joo, et al.
Publicado: (2020)

Expression and Prognostic Value of Tumor-Infiltrating Lymphocytes and PD-L1 in Hepatocellular Carcinoma
por: Nie, Hanxiao, et al.
Publicado: (2021)

Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pleomorphic Lobular Breast Carcinoma
por: Göker, Menekse, et al.
Publicado: (2023)

The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD‐L1 expression and tumor‐infiltrating lymphocytes
por: Chen, Lu, et al.
Publicado: (2019)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Regulatory Effect of PD1/PD-Ligand 1 (PD-L1) on Treg Cells in Patients with Idiopathic Pulmonary Fibrosis
por: Wang, Bing, et al.
Publicado: (2021)

Determining the optimal PD‐1/PD‐L1 inhibitors for the first‐line treatment of non‐small‐cell lung cancer with high‐level PD‐L1 expression in China
por: Teng, Meng‐Meng, et al.
Publicado: (2021)

PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes
por: Liu, Bin, et al.
Publicado: (2018)

Relationship between Aldehyde Dehydrogenase, PD-L1 and Tumor-Infiltrating Lymphocytes with Pathologic Response and Survival in Breast Cancer
por: López Flores, Mariana, et al.
Publicado: (2022)

Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse
por: Guo, Haoyue, et al.
Publicado: (2021)

iNOS Expression by Tumor-Infiltrating Lymphocytes, PD-L1 and Prognosis in Non-Small-Cell Lung Cancer
por: Giatromanolaki, Alexandra, et al.
Publicado: (2020)

PD-L1 correlated gene expression profiles and tumor infiltrating lymphocytes in pancreatic cancer
por: Li, Jiajin, et al.
Publicado: (2021)

Expression of immune checkpoints (PD-L1 and IDO) and tumour-infiltrating lymphocytes in breast cancer
por: Alkhayyal, Noura, et al.
Publicado: (2022)

Ocular adverse events in PD-1 and PD-L1 inhibitors
por: Young, LeAnne, et al.
Publicado: (2021)

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
por: Darb-Esfahani, Silvia, et al.
Publicado: (2015)

A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers
por: Ayers, Kristin L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sqi8tr7egmcfjmgvs4e6qdheij